Publication Name	World Journal of Gastroenterology
Manuscript ID	18017
Country	Japan

Received	2015-04-03 08:30
Peer-Review Started	2015-04-04 15:17
To Make the First Decision	2015-04-23 13:17
Return for Revision	2015-04-30 17:14
Revised	2015-05-08 17:43
Second Decision	2015-07-03 21:01
Accepted by Journal Editor-in-Chief	2015-07-05 14:39
Accepted by Executive Editor-in-Chief	2015-07-08 17:36
Articles in Press	2015-07-08 17:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-03 11:20
Publish the Manuscript Online	2015-08-08 15:26

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2
Manuscript Source	Invited Manuscript
All Author List	Satoshi Tanida, Tsutomu Mizoshita, Keiji Ozeki, Takahito Katano, Hiromi Kataoka, Takeshi Kamiya and Takashi Joh
Funding Agency and Grant Number	Funding Agency Grant Number Scientific Research (C) 25460957
Corresponding Author	Satoshi Tanida, MD, PhD, Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya city Aichi prefecture, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan. stanida@med.nagoya-cu.ac.jp
Key Words	Tumor necrosis factor-α; Shedding; Integrin α4β7; Epidermal growth factors
Core Tip	The main goal of ulcerative colitis (UC) therapy is to induce and maintain long-term corticosteroid-free remission. Therapies such as anti-tumor necrosis factor (TNF)-? and integrin ?4?7 neutralizing antibodies have emerged in recent times, but are not universally efficacious; additional treatments are needed. We have recently demonstrated that annexin (ANX) A2 inhibition may be a new therapeutic strategy to prevent TNF-? shedding during inflammatory bowel disease (IBD) inflammation. Here we focus on effective therapies for UC patients that are currently available, or will be in the near future, and the potential of ANX A2 as a new molecular target for IBD treatment.
Publish Date	2015-08-08 15:26
Citation	Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786
URL	http://www.wjgnet.com/1007-9327/full/v21/i29/8776.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i29.8776

Full Article (PDF)	WJG-21-8776.pdf
Full Article (Word)	WJG-21-8776.doc
Manuscript File	18017-Review.docx
Answering Reviewers	18017-Answering reviewers.pdf
Audio Core Tip	18017-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	18017-Conflict-of-interest statement.pdf
Copyright License Agreement	18017-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	18017-Language certificate.pdf
Peer-review Report	18017-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	18017-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	18017-Scientific misconduct check.pdf
Scientific Editor Work List	18017-Scientific editor work list.pdf